The availability of disease-specific genomic data is critical for developing new computational methods that predict the pathogenicity of human variants and advance the field of precision medicine. However, the lack of gold standards to properly train and benchmark such methods is one of the greatest challenges in the field. In response to this challenge, the scientific community is invited to participate in the Critical Assessment for Genome Interpretation (CAGI), where unpublished disease variants are available for classification by in silico methods. As part of the CAGI-5 challenge, we evaluated the performance of 18 submissions and three additional methods in predicting the pathogenicity of single nucleotide variants (SNVs) in checkpoint kinase 2 (CHEK2) for cases of breast cancer in Hispanic females. As part of the assessment, the efficacy of the analysis method and the setup of the challenge were also considered. The results indicated that though the challenge could benefit from additional participant data, the combined generalized linear model analysis and odds of pathogenicity analysis provided a framework to evaluate the methods submitted for SNV pathogenicity identification and for comparison to other available methods. The outcome of this challenge and the approaches used can help guide further advancements in identifying SNV-disease relationships.

Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer / Voskanian A.; Katsonis P.; Lichtarge O.; Pejaver V.; Radivojac P.; Mooney S.D.; Capriotti E.; Bromberg Y.; Wang Y.; Miller M.; Martelli P.L.; Savojardo C.; Babbi G.; Casadio R.; Cao Y.; Sun Y.; Shen Y.; Garg A.; Pal D.; Yu Y.; Huff C.D.; Tavtigian S.V.; Young E.; Neuhausen S.L.; Ziv E.; Pal L.R.; Andreoletti G.; Brenner S.E.; Kann M.G.. - In: HUMAN MUTATION. - ISSN 1059-7794. - STAMPA. - 40:9(2019), pp. 1612-1622. [10.1002/humu.23849]

Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer

Capriotti E.;Martelli P. L.;Savojardo C.;Babbi G.;Casadio R.;
2019

Abstract

The availability of disease-specific genomic data is critical for developing new computational methods that predict the pathogenicity of human variants and advance the field of precision medicine. However, the lack of gold standards to properly train and benchmark such methods is one of the greatest challenges in the field. In response to this challenge, the scientific community is invited to participate in the Critical Assessment for Genome Interpretation (CAGI), where unpublished disease variants are available for classification by in silico methods. As part of the CAGI-5 challenge, we evaluated the performance of 18 submissions and three additional methods in predicting the pathogenicity of single nucleotide variants (SNVs) in checkpoint kinase 2 (CHEK2) for cases of breast cancer in Hispanic females. As part of the assessment, the efficacy of the analysis method and the setup of the challenge were also considered. The results indicated that though the challenge could benefit from additional participant data, the combined generalized linear model analysis and odds of pathogenicity analysis provided a framework to evaluate the methods submitted for SNV pathogenicity identification and for comparison to other available methods. The outcome of this challenge and the approaches used can help guide further advancements in identifying SNV-disease relationships.
2019
Assessing the performance of in silico methods for predicting the pathogenicity of variants in the gene CHEK2, among Hispanic females with breast cancer / Voskanian A.; Katsonis P.; Lichtarge O.; Pejaver V.; Radivojac P.; Mooney S.D.; Capriotti E.; Bromberg Y.; Wang Y.; Miller M.; Martelli P.L.; Savojardo C.; Babbi G.; Casadio R.; Cao Y.; Sun Y.; Shen Y.; Garg A.; Pal D.; Yu Y.; Huff C.D.; Tavtigian S.V.; Young E.; Neuhausen S.L.; Ziv E.; Pal L.R.; Andreoletti G.; Brenner S.E.; Kann M.G.. - In: HUMAN MUTATION. - ISSN 1059-7794. - STAMPA. - 40:9(2019), pp. 1612-1622. [10.1002/humu.23849]
Voskanian A.; Katsonis P.; Lichtarge O.; Pejaver V.; Radivojac P.; Mooney S.D.; Capriotti E.; Bromberg Y.; Wang Y.; Miller M.; Martelli P.L.; Savojardo C.; Babbi G.; Casadio R.; Cao Y.; Sun Y.; Shen Y.; Garg A.; Pal D.; Yu Y.; Huff C.D.; Tavtigian S.V.; Young E.; Neuhausen S.L.; Ziv E.; Pal L.R.; Andreoletti G.; Brenner S.E.; Kann M.G.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/715314
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact